<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811991</url>
  </required_header>
  <id_info>
    <org_study_id>HR-DYXAJF-Ⅲ</org_study_id>
    <nct_id>NCT02811991</nct_id>
  </id_info>
  <brief_title>A PhaseⅡ/ Ⅲ Seamless Study to Evaluate Efficacy and Safety of Paracetamol Injection as Adjuvant to Morphine-based Postoperative Analgesia</brief_title>
  <official_title>A PhaseⅡ/ Ⅲ Seamless Study to Evaluate Efficacy and Safety of Paracetamol Injection as Adjuvant to Morphine-based Postoperative Analgesia—Multicentered, Randomized, Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paracetamol,a classical analgesic agent,constitutes an essential component of multi-modal
      analgesia. This medication is generally safe, well tolerated and effective within recommended
      daily dose.The purpose of the study is to evaluate the efficacy and safety of Paracetamol
      Injection as adjuvant to morphine-based post-operative analgesia, as well as to explore the
      reasonable dosage of paracetamol among Chinese population under above-mentioned circumstance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total morphine use in 24 hours</measure>
    <time_frame>24h after the 1st dose of study drug</time_frame>
    <description>Total morhpine use(including PCA and emergency morphine use)in 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity VAS AUC(0-24h) at rest</measure>
    <time_frame>0-24h PI VAS AUC(mesured at 1h、3h、6h、12h、24h after the 1st dose of study drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity VAS AUC(0-24h) at movement</measure>
    <time_frame>0-24h PI VAS AUC(mesured at 1h、3h、6h、12h、24h after the 1st dose of study drug)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of mophine-related ADR</measure>
    <time_frame>0-24h after the 1st dose of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">348</enrollment>
  <condition>Post-operative Analgesia</condition>
  <arm_group>
    <arm_group_label>Experimental:Paracetamol Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>325mg(32.5mL)or 500mg(50mL) iv q6h according to assignment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo:Normal Saline Injcetion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>32.5mLor 50mL iv q6h according to assignment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol injection</intervention_name>
    <description>325mg(32.5mL) or 500mg(50mL) iv q6h,4 doses in 24h.Infushion time≥15min.</description>
    <arm_group_label>Experimental:Paracetamol Injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline injection</intervention_name>
    <description>32.5mL or 50mL iv q6h,4 doses in 24h.Infushion time≥15min.</description>
    <arm_group_label>Placebo:Normal Saline Injcetion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morhpine PCA</intervention_name>
    <description>Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose&lt;25mg/4h.</description>
    <arm_group_label>Experimental:Paracetamol Injection</arm_group_label>
    <arm_group_label>Placebo:Normal Saline Injcetion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged from 18 to 70 years inclusively, male or female;

          -  Patients scheduled for open abdominal surgery(such as gall bladder, lower abdominal
             investigative surgery), gynecologic surgery(such as trans-abdominal hysterectomy),
             orthopedic surgery(such as replacement and reconstruction of knee, hip or shoulder
             joint), with anticipated need for post-operative iv. morphine analgesia≥24h;

          -  18kg/m2≤BMI≤30 kg/m2;

          -  Classified as ASA risk class I, II according to the American Society of
             Anesthesiologists;

          -  Able to understand the study procedures and the use of the pain scales, able to
             operate a patient controlled analgesia (PCA) device and to communicate meaningfully
             with the study observer and staff;

          -  Patients free of any contraindication to the study drugs, morphine and to the
             standardized anesthesia protocol;

          -  Clearly understand the procedure of study, voluntarily participate and provided
             written consent form.

        Exclusion Criteria:

          -  Impaired liver function (ALT and/or AST &gt; 2 x upper limit of normal range, or TBIL≥1.5
             x upper limit of normal range);

          -  Impaired renal function(Serum Creatinine &gt;176μmoL/L), or undergoing dialysis within 28
             days before surgery;

          -  Patients at high risk for bleeding, including congenital hemorrhagic disease(such as
             Hemophilia), Thrombocytopenia(CBC PLT&lt;30×109/L), Qualitative Plateletdefects(such as
             ITP, DIC, congenital abonormal platelet), or clinically significant active bleeding;

          -  Abnormal resting ECG, judged as not eligible for entry by investigator;

          -  Hypertensive patients not achieving satisfactory BP control under hypertensive
             medication(Sitting SBP≥160mm Hg, and/or DBP≥105mm Hg during screen period);

          -  Sitting SBP≤90mm Hg during screening period;

          -  Diabetic Patients not achieving satisfactory blood glucose control(FBG≥11.1moL/L
             during screening period);

          -  Known history of bronchial asthma, pulmonary heart disease or heart failure;

          -  Participation in other trials within 30 days;

          -  Pregnant women or women in lactation;

          -  Patients not eligible due to other reasons judged by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fei Liu, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huilong Liu, M.A.</last_name>
    <email>Liuhuilong@hrs.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Yue, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Tian, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mingzhang Zuo, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The South West Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaizhi Lu, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fuzhou General Hospital of Nanjing Millitary Command</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guozhong Chen, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liuzhou General Hospital</name>
      <address>
        <city>Liuzhou</city>
        <state>Guangxi</state>
        <zip>545006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Zhen, M.A</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guizhou Provincial People's Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <zip>551100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Sun, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongtai Han, M.A.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Third Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Ouyang, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.1 People's Hospital of Chenzhou City</name>
      <address>
        <city>Chenzhou</city>
        <state>Hunan</state>
        <zip>423000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xungang Xiao, M.A</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital,Jiangnan University</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214062</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yong Ji, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haichun Ma, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated to Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoqing Zhang, M.A</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital</name>
      <address>
        <city>Chendu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fei Liu, Ph.D</last_name>
      <email>303333870@qq.com</email>
    </contact>
    <investigator>
      <last_name>Fei Liu, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin Liu, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yonghao Yu, Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo No.2 Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingjiang Pang, Ph.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>paracetamol</keyword>
  <keyword>post-operative analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

